Effect of theophylline on respiratory muscle function

Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease

Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are among the leading causes of mortality worldwide. Cigarette smoking is among the main aetiologic factors for both ailments. These diseases share common pathogenetic mechanisms including inflammation, oxidative stress, and tissue remodelling. Current therapeutic approaches are limited by low efficacy and adverse effects. Consequentially, LC has a 5-year survival of < 20%, while COPD is incurable, underlining the necessity for innovative treatment strategies. Two promising emerging classes of therapy against these diseases include plant-derived molecules (phytoceuticals) and nucleic acid-based therapies. The clinical application of both is limited by issues including poor solubility, poor permeability, and, in the case of nucleic acids, susceptibility to enzymatic degradation, large size, and electrostatic charge density. Nanoparticle-based advanced drug delivery systems are currently being explored as flexible systems allowing to overcome these limitations. In this review, an updated summary of the most recent studies using nanoparticle-based advanced drug delivery systems to improve the delivery of nucleic acids and phytoceuticals for the treatment of LC and COPD is provided. This review highlights the enormous relevance of these delivery systems as tools that are set to facilitate the clinical application of novel categories of therapeutics with poor pharmacokinetic properties.

Managing respiratory muscle weakness during weaning from invasive ventilation

Weaning is a critical stage of an intensive care unit (ICU) stay, in which the respiratory muscles play a major role. Weakness of the respiratory muscles, which is associated with significant morbidity in the ICU, is not limited to atrophy and subsequent dysfunction of the diaphragm; the extradiaphragmatic inspiratory and expiratory muscles also play important parts. In addition to the well-established deleterious effect of mechanical ventilation on the respiratory muscles, other risk factors such as sepsis may be involved. Weakness of the respiratory muscles can be suspected visually in a patient with paradoxical movement of the abdominal compartment. Measurement of maximal inspiratory pressure is the simplest way to assess respiratory muscle function, but it does not specifically take the diaphragm into account. A cut-off value of -30 cmH₂O could identify patients at risk for prolonged ventilatory weaning; however, ultrasound may be better for assessing respiratory muscle function in the ICU. Although diaphragm dysfunction has been associated with weaning failure, this diagnosis should not discourage clinicians from performing spontaneous breathing trials and considering extubation. Recent therapeutic developments aimed at preserving or restoring respiratory muscle function are promising.

Xanthines and Phosphodiesterase Inhibitors

Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug interactions. However, lower than conventional doses of theophylline considered to be bronchodilator are now known to have anti-inflammatory actions of relevance to the treatment of respiratory disease. The molecular mechanism(s) of action of theophylline are not well understood, but several potential targets have been suggested including non-selective inhibition of phosphodiesterases (PDE), inhibition of phosphoinositide 3-kinase, adenosine receptor antagonism and increased activity of certain histone deacetylases. Although theophylline has a narrow therapeutic window, other xanthines are in clinical use that are claimed to have a better tolerability such as doxofylline and bamifylline. Nonetheless, xanthines still play an important role in the treatment of asthma and COPD as they can show clinical benefit in patients who are refractory to glucocorticosteroid therapy, and withdrawal of xanthines from patients causes worsening of disease, even in patients taking concomitant glucocorticosteroids.More recently the orally active selective PDE4 inhibitor, roflumilast, has been introduced into clinical practice for the treatment of severe COPD on top of gold standard treatment. This drug has been shown to improve lung function in patients with severe COPD and to reduce exacerbations, but is dose limited by a range side effect, particularly gastrointestinal side effects.

Cough reflex is additively potentiated by inputs from the laryngeal and tracheobronchial [corrected] receptors and enhanced by stimulation of the central respiratory neurons

The cough is an essential airway defense reflex. In this study we investigated the coordination of inputs from the laryngeal and tracheobronchial receptors in the cough reflex. In 15 beagle dogs (7-9 kg) lightly anesthetized with intravenous profobol (20-30 mg/kg/h), the cough response was elicited with mechanical stimulation of either the vocal chord or tracheal bifurcation. Simultaneous stimulation of both sites increased all the parameters of cough strength, that is, mean pleural pressure (P (pl)), mean expiratory flow, number of cough bouts, and cough duration, in comparison with stimulation of the sites individually. The increases in mean P (pl) and cough duration reached statistical significance (13.3 vs. 18.4 cmH(2)O and 13.3 vs. 18.2 s, respectively). When the anesthetic level became deeper, the prolongation of cough duration almost disappeared, but the augmentation of mean P (pl) was much less affected. During stimulation of the central respiratory neurons by intravenous dimorphoramine or acute hyperoxic hypercapnia, the cough strength increased significantly. We concluded that inputs from the laryngeal and tracheobonchial cough receptors acted in concert and potentiated the cough reflex. Furthermore, stimulation of the central respiratory neurons may increase the intensity of a cough response.

Ventilatory management in patients with chronic airflow obstruction

Mechanical ventilatory support allows patients who have CAO to gain time for pharmacologic treatment to work and to avoid and/or recover from respiratory muscle fatigue. The cornerstone to avoiding associated morbidity with mechanical ventilation in these patients is to prevent dynamic hyperinflation of the lung by limiting minute ventilation and maximizing time for expiration and by inducing synchronization between the patient and mechanical ventilator. When mechanical ventilation is necessary, NPPV should be considered first, whenever possible, in these patients. Patients who have CAO requiring mechanical ventilatory support have an increased risk of death following such an event. Therefore, careful followup is needed after hospital discharge.

Oral theophylline for chronic obstructive pulmonary disease

BACKGROUND

Oral theophylline has, for many years, been used as a bronchodilator in patients with COPD. Despite the introduction of new drugs, and its narrow therapeutic index, theophylline is still recommended for COPD treatment.

OBJECTIVES

To determine the effectiveness of oral theophylline when compared to placebo in patients with stable COPD.

SEARCH STRATEGY

The Cochrane Airways Review Group and Cochrane Controlled Clinical Registers were searched.

SELECTION CRITERIA

All studies were randomised controlled trials (RCTs).

DATA COLLECTION AND ANALYSIS

Data were independently abstracted and the methodological quality assessed by two reviewers.

MAIN RESULTS

Twenty RCTs met the inclusion criteria. Concomitant therapy varied from none to any other bronchodilator plus corticosteroid (oral and inhaled). The following outcomes were significantly different when compared to placebo. FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml. Similarly for FVC: WMD 210 ml 95%CI 100, 320. Two studies reported an improvement in VO2max; WMD 195 ml/min, 95%CI 113,27). At rest, PaO2 and PaCO2 both improved with treatment (WMD 3.2 mmHg; 95%CI = 1.2, 5., and WMD -2.4 mmHg; 95%CI = -3.5, -1.2, respectively). Walking distance tests did not improve (4 studies, Standardised Mean Difference 0.30, 95%CI -0.01, 0.62), neither did Visual Analogue Score for breathlessness isn two small studies (WMD 3.6, 95%CI -4.6, 11.8). The Relative Risk (RR) of nausea was greater with theophylline (RR 7.7; 95%CI 1.5, 39.9). However, patients' preference for theophylline was greater than that for placebo (RR 2.27; 95%CI = 1.26, 4.11). Very few patient withdrew from these studies for any reason.

REVIEWER'S CONCLUSIONS

Theophylline has a modest effect on FEV1 and FVC and slightly improves arterial blood gas tensions in moderate to severe COPD. These benefits were seen in patients receiving a variety of different concomitant therapies. Improvement in exercise performance depended on the method of testing. There was a very low dropout rate in the studies that could be included in this review, which suggests that recruited patients may have been known by the investigators to be theophylline tolerant. This may limit the generalisability of these studies.

Acute asthma

OBJECTIVE: Asthma is the most common medical emergency in children. It is associated with significant morbidity and mortality rates and poses a tremendous societal burden worldwide. Management of the acute attack involves a stepwise approach that includes beta-agonist and steroid therapy, the mainstay of emergency treatment. Most patients will respond to this regime and can be discharged from the emergency department. Failure to respond to treatment necessitates hospital admission and sometimes admission to the intensive care unit (ICU). Management in the ICU involves intensification of pharmacologic therapy, including nonstandard therapies, in an attempt to avoid intubation and ventilation. When needed, mechanical ventilatory support can be rendered fairly safe with little morbidity if the likely cardiorespiratory physiologic derangements are appreciated and if appropriate ventilatory strategies are used. In the past two decades, the availability of newer potent medications and changes in approach to monitoring and ventilatory strategies have resulted in a decrease in ICU morbidity and mortality rates. Research endeavors are presently underway to further characterize the underlying mechanisms of the disease and are likely to lead to novel therapies. This article reviews the approach to management of acute severe asthma.

Impaired ventilatory capacity after recovery from Guillain-Barré syndrome

A 48-year-old woman who failed to disclose significant past medical history presented for laparoscopic-assisted vaginal hysterectomy with general anesthesia. After the uneventful induction of anesthesia, her trachea could not be intubated due to an extremely anterior larynx, and she was allowed to awaken. However, she developed upper airway obstruction and displayed marked muscle weakness with inadequate tidal volumes and marginal oxygen saturation. A history of prior Guillain-Barré syndrome was disclosed by the attending gynecologist. The patient's recovery was complicated by the development of postobstructive pulmonary edema and by respiratory insufficiency requiring the use of mask continuous positive airway pressure (CPAP). Despite vigorous diuresis, her respiratory status and muscle weakness did not significantly improve until she received a trial of aminophylline by infusion, after which she was able to be weaned from mask CPAP support. The patient was discharged home and returned 8 weeks later for surgery. She underwent awake fiberoptic intubation, after which general anesthesia was induced and maintained without complication. An aminophylline infusion was used in the perioperative period until the patient was successfully awakened and her trachea extubated. The frequency of residual muscle weakness after apparent full recovery from Guillain-Barré syndrome is discussed, along with the rationale for the use of aminophylline in this patient's clinical management.

Effects of alkylxanthines on contractility of diaphragm fibres isolated from normal and sensitized guinea-pigs

This study investigates the effects of alkylxanthines on twitch tension generated by electrical stimulation (supramaximal pulses, 0.2 ms duration, 1 Hz) of diaphragm muscle fibres isolated from normal and actively-sensitized guinea-pigs. Caffeine, theophylline and theobromine increased, in a concentration-dependent manner (50-500 microM), twitch tension in normal and sensitized diaphragm. Caffeine (500 microM) enhanced contractility to a greater extent than theophylline or theobromine. Twitch potentiation by caffeine (500 microM) was significantly greater in sensitized diaphragm. Verapamil (0.1-100 microM) did not alter twitch contractions in the absence or presence of alkylxanthines in normal or sensitized strips. Dantrolene (0.01-100 microM) depressed, in a concentration-dependent fashion, twitch contractions of normal and sensitized diaphragm. The inhibitory concentration 50% (expressed as -log IC50) was 6.78 +/- 0.13 in normal tissues and 6.15 +/- 0.11 in sensitized tissues (n = 6 in each group; P < 0.05). Exposure to Ca(2+)-free, EGTA (0.1 mM)-containing medium, depressed twitch contraction of normal diaphragm to a lesser extent than that of sensitized diaphragm. Methylxanthines reversed depression of twitch contractions produced by exposure to dantrolene (5 microM) or a Ca(2+)-free medium. Adenosine (1-1000 microM) was without effect whereas enprofylline (50-500 microM) enhanced diaphragm contractility in normal tissues. This indicates that blockade of adenosine receptors is not involved in the inotropic effect of alkylxanthines in guinea-pig diaphragm. Results from this study suggest that alkylxanthines enhance diaphragm contractility in the guinea-pig by releasing intracellular Ca2+ and promoting extracellular Ca2+ entry through verapamil-insensitive pathways. An alteration of Ca2+ movements and stores may be present in the sensitized diaphragm.

Cutaneous metabolism of theophylline by the human skin

Percutaneous absorption of theophylline in human skin from five sources was examined by use of a flow-through in vitro diffusion system. The metabolites and unchanged drug were estimated by thin-layer chromatography. Correlation was evident in the percentage of the applied dose that diffused through the five skin samples (range 2.8 +/- 0.5%-7.7 +/- 0.8%); however, the percentage of applied dose absorbed varied between different skin samples (range 3.6 +/- 0.9%-33.4 +/- 2.4%). Between 0.2 +/- 0.1%-4.6 +/- 0.2% of the doses applied were metabolized, and over 60% of the total metabolites formed diffused through the skin. The uptake and metabolism of theophylline by microsomes obtained from four of the human skin samples were measured. All preparations showed detectable activities for the metabolism of theophylline. Microsomal preparations from skin sources A, B, and E, and B, C, and E biotransformed theophylline to 1,3,7-trimethyluric acid and 1,3-dimethyluric acid, respectively. The activities of microsomes from skin samples C and E on the drug produced the pharmacologically active metabolite 3-methylxanthine. The specific activities of the microsomes from skin sources A-E for the formation of 1,3-dimethyluric acid and 3-methylxanthine varied fivefold. However, the variation in specific activities of the microsomes for the formation of 1,3,7-trimethyluric acid was twofold (range 2.8 +/- 0.1-6.2 +/- 0.5 pmol/min per mg protein). These metabolic data may be of value in the development of transdermal theophylline systems. The results indicate that a high level of absorption enhancement will be required before transdermal theophylline preparations could produce therapeutic plasma concentrations.

Is theophylline use justified in acute exacerbations of asthma?

Despite widespread use of theophylline in the hospital management of asthma, supportive data justifying its use are sparse. Clinical research in the 1980s has forced a serious new examination of the drug's role in acute exacerbations of asthma. Because of the morbidity, mortality, questionable value, and overall cost of theophylline therapy, this reevaluation is of particular importance. Enhanced knowledge of the value of treatment with intensive inhaled beta agonists, systemic glucocorticoids, and inhaled ipratropium should prompt elimination of the routine, initial use of theophylline in emergency room care of most asthmatics. Further research is necessary to justify the routine, initial use of the drug in hospitalized asthmatics.

Terbutaline and diaphragm function in chronic obstructive pulmonary disease: a double-blind randomized clinical trial

We conducted a double-blind, randomized crossover trial to evaluate whether oral terbutaline (2.5 mg orally three times daily for a week) increased the force of diaphragmatic contraction in normocapnic patients with chronic obstructive pulmonary disease. Ten patients with moderate to severe airway obstruction completed the trail. Compared with placebo, terbutaline produced a mean increase of 5.8 cmH2O in peak inspiratory mouth pressure and a mean increase of 5.0 cmH2O in transdiaphragmatic pressure during a maximal inspiratory manoeuvre. These small changes with terbutaline failed to achieve statistical significance. Also, terbutaline failed to alter flow rates (FEV1, Vmax50) or patients' dyspnoea ratings using two separate clinical scales (Pneumoconiosis Research Unit Score and the Modified Dyspnoea Index). Because all observed changes in respiratory muscle strength were small and because the trial had power to detect small changes in inspiratory mouth pressures, we suggest that oral terbutaline at the dose administered in this study has little noteworthy effect on respiratory muscle strength in normocapnic patients with chronic obstructive pulmonary disease.